Treats edema associated with congestive heart failure, cirrhosis … the nephrotic syndrome. Sold as Dyrenium. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 15, 2026, FDA lists 4 applications for Triamterene (sold as Dyrenium), first approved Aug 10, 1964, with 0 new uses approved and 0 published complete response letters.
| Triamterene | Part D | $4.2M | -1% | 3,002 |
| Dyrenium | Part D | $193K | -26% | 44 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Treatment of Meniere's Disease With Migraine MedicationsMénière · University of California, Irvine | Phase 4 | Recruiting | Oct 17, 2022 |
| Aug 10, 1964 | DyreniumNDA 13174 · New molecular entity | Advanz Pharma | 39 | Marketed |
| Aug 19, 2019 | TriamtereneANDA 211581 | Tp Anda Holdings | 0 | Marketed |
| Jul 6, 2022 | TriamtereneANDA 214768 | Biocon Generics | 0 | Marketed |
| Oct 28, 2026 | TriamtereneANDA 220782 | Rubicon Research | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
